FGFR2 and neoplasm: Most importantly, if molecular stratification of the tumor is possible, then immunological treatment or molecularly targeted options should be examined, such as fibroblast growth factor receptor 2 (FGFR2) fusion eligible for treatment with pemigatinib, which has been recently approved, isocitrate dehydrogenase-1 (IDH-1) mutation eligible for treatment with ivosidenib, or microsatellite instability eligible for treatment with pembrolizumab (17–19).